A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome is a research paper published in Human Molecular Genetics (2022). On theSindex it has a DataRank of 0.908. It has been cited 35 times, with 25 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.538
From this paper's citation signal
Citation Network Contribution
0.370
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 25 citers.
NINDS NIH HHS
Grant: K23 NS119666
NICHD NIH HHS
Grant: P50 HD105351
NINDS NIH HHS
Grant: U54 NS092090
Data Management and Coordinating Center
Grant: U2CTR002818
National Institutes of Health
Grant: 1K23NS119666-01A1
Investigating the Genetic Landscape of Cerebral Palsy
National Institutes of Health
Grant: 5P50HD105351-02
Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center
National Institutes of Health
Grant: 5U2CTR002818-03
Data Management and Coordinating Center: Rare Diseases Clinical Research Network
National Institutes of Health
Grant: 1U54NS092090-01
Developmental Synaptopathies Associated with TSC, PTEN and SHANK3 Mutations
National Institute of Child Health and Human Development
National Institute of Mental Health
Rare Diseases Research
Rare Diseases Clinical Research Network
National Center for Advancing Translational Sciences
National Institute of Neurological Disorders and Stroke
FWCI
3.52
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals